IRONWOOD PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year One
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Long-Term Debt, Maturity, Year One of $201.50 million as of 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2025-11-10
- 2025-09-30: Long-Term Debt, Maturity, Year One $201.50M.
- 2025-06-30: Long-Term Debt, Maturity, Year One $201.50M.
- 2025-03-31: Long-Term Debt, Maturity, Year One $201.50M.
- 2024-09-30: Long-Term Debt, Maturity, Year One $3.00M.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2025-09-30 | $201.50M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $201.50M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $201.50M 10-Q · filed 2025-05-12 |
| 2024-09-30 | $3.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $3.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.00M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $203.75M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $203.75M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $203.75M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.50M 10-K · filed 2023-02-16 |
| 2022-09-30 | $4.50M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.50M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $4.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $126.56M 10-K · filed 2022-02-18 |
| 2021-09-30 | $126.56M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $126.56M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $126.56M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $7.22M 10-K · filed 2021-02-17 |
| 2020-09-30 | $7.22M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $7.22M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |